ARTICLE | Company News
Isis, Merck deal
January 6, 2003 8:00 AM UTC
ISIS reacquired rights from MRK to ISIS 113715, an antisense inhibitor of PTP-1b phosphatase in preclinical development for Type II diabetes. The company said it plans to begin clinical testing of th...